share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A：超过5%持股股东披露文件(修正)-The Vanguard Group(5.40%)
美股SEC公告 ·  2024/11/12 23:36

Moomoo AI 已提取核心信息

The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 12, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group's clients, including registered investment companies and other managed accounts, are entitled to receive dividends from or proceeds from the sale of these securities. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, nor in connection with any transaction having that purpose or effect.
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 12, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group's clients, including registered investment companies and other managed accounts, are entitled to receive dividends from or proceeds from the sale of these securities. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, nor in connection with any transaction having that purpose or effect.
先锋集团于2024年11月12日向证券交易委员会提交了修订后的13G/A表格，说明其对bluebird bio, Inc.普通股的持股发生了变化。截止到2024年9月30日，先锋集团报告称其持有bluebird bio的10,474,007股股份，代表着公司普通股类别的5.40%。该文件显示，先锋集团对87,543股股份拥有共享投票权，对10,330,825股股份拥有独占处置权，并且还对143,182股股份拥有额外的共享处置权。先锋集团的客户，包括注册投资公司和其他管理账户，有权从这些证券中获得分红派息或出售的收益。该文件声明这些证券并不是为了改变或影响bluebird bio的控制权而收购的，也与任何具有该目的或效果的交易无关。
先锋集团于2024年11月12日向证券交易委员会提交了修订后的13G/A表格，说明其对bluebird bio, Inc.普通股的持股发生了变化。截止到2024年9月30日，先锋集团报告称其持有bluebird bio的10,474,007股股份，代表着公司普通股类别的5.40%。该文件显示，先锋集团对87,543股股份拥有共享投票权，对10,330,825股股份拥有独占处置权，并且还对143,182股股份拥有额外的共享处置权。先锋集团的客户，包括注册投资公司和其他管理账户，有权从这些证券中获得分红派息或出售的收益。该文件声明这些证券并不是为了改变或影响bluebird bio的控制权而收购的，也与任何具有该目的或效果的交易无关。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 114.220
    ABVC BioPharma
    ABVC
    -- 1.0600
    bluebird bio
    BLUE
    -- 4.880
    NLS Pharmaceutics
    NLSP
    -- 1.5400
    DBV Technologies
    DBVT
    -- 6.820
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点